Publications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (117)

2024

  1. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  3. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry

  4. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  5. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  6. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  7. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

2023

  1. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  4. Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

    BioFactors, Vol. 49, Núm. 4, pp. 912-927

  5. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

  6. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  3. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  4. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  5. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies

    Advances in Cancer Research (Academic Press Inc.), pp. 367-413

  6. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission

    Medicina Clinica

  7. Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease

    Journal of Physiology and Biochemistry, Vol. 78, Núm. 1, pp. 229-243